Chen VE, Gillespie EF, Zakeri K, Murphy JD, Yashar CM, Lu S, Einck JP (2017) Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer. Adv Radiat Oncol 2(2):105–109

Article  PubMed  PubMed Central  Google Scholar 

Chen X, He C, Han D, Zhou M, Wang Q, Tian J, Li L, Xu F, Zhou E, Yang K (2017) The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. Future Oncol 13(9):843–857

Article  PubMed  Google Scholar 

Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, Siewertsz van Reesema LL, Tang-Tan AM, Guye ML, Chang DZ, Winston JS et al (2020) Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies. Cancers (Basel) 12(9):2392

Article  PubMed  Google Scholar 

Finkelman BS, Zhang H, Hicks DG, Turner BM (2023) The evolution of Ki-67 and breast carcinoma: past observations, present directions, and future considerations. Cancers (Basel) 15(3):808

Article  PubMed  Google Scholar 

Ács B, Zámbó V, Vízkeleti L, Szász AM, Madaras L, Szentmártoni G, Tőkés T, Molnár B, Molnár IA, Vári-Kakas S et al (2017) Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy. Diagn Pathol 12(1):20

Article  PubMed  PubMed Central  Google Scholar 

Jain P, Doval DC, Batra U, Goyal P, Bothra SJ, Agarwal C, Choudhary DK, Yadav A, Koyalla VPB, Sharma M et al (2019) Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer. Jpn J Clin Oncol 49(4):329–338

Article  PubMed  Google Scholar 

Yamamoto S, Ibusuki M, Yamamoto Y, Fu P, Fujiwara S, Murakami K, Iwase H (2013) Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens. Breast Cancer 20(3):262–270

Article  PubMed  Google Scholar 

Luporsi E, André F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A et al (2012) Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 132(3):895–915

Article  PubMed  Google Scholar 

Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M (2021) Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 32(10):1216–1235

Article  PubMed  Google Scholar 

Srivastava P, Wang T, Clark BZ, Yu J, Fine JL, Villatoro TM, Carter GJ, Brufsky AM, Gorantla VC, Huggins-Puhalla SL et al (2022) Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers. NPJ Breast Cancer 8(1):51

Article  PubMed  PubMed Central  Google Scholar 

Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, Dabbs DJ (2009) Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol 2(5):444–455

PubMed  PubMed Central  Google Scholar 

Wu Q, Ma G, Deng Y, Luo W, Zhao Y, Li W, Zhou Q (2019) Prognostic value of Ki-67 in patients with resected triple-negative breast cancer: a meta-analysis. Front Oncol 9:1068

Article  PubMed  PubMed Central  Google Scholar 

Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, Di G, Liu G, Yu K, Shao Z et al (2020) The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep 10(1):225

Article  PubMed  PubMed Central  Google Scholar 

Cserni G, Quinn CM, Foschini MP, Bianchi S, Callagy G, Chmielik E, Decker T, Fend F, Kovács A, van Diest PJ et al (2021) Triple-negative breast cancer histological subtypes with a favourable prognosis. Cancers (Basel) 13(22):5694

Article  PubMed  Google Scholar 

Ding Y, Ding K, Qian H, Yu X, Zou D, Yang H, Mo W, He X, Zhang F, Qin C et al (2020) Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer. PLoS ONE 15(4):e0231895

Article  PubMed  PubMed Central  Google Scholar 

Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Fujisue M, Toyozumi Y, Arima N (2014) Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer. Mol Clin Oncol 2(6):1062–1068

Article  PubMed  PubMed Central  Google Scholar 

Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N (2010) Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer 17(4):269–275

Article  PubMed  Google Scholar 

Li L, Han D, Wang X, Wang Q, Tian J, Yao J, Yuan L, Qian K, Zou Q, Yi W et al (2017) Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis. Future Oncol 13(11):1021–1034

Article  PubMed  Google Scholar 

Elnemr GM, El-Rashidy AH, Osman AH, Issa LF, Abbas OA, Al-Zahrani AS, El-Seman SM, Mohammed AA, Hassan AA (2016) Response of triple negative breast cancer to neoadjuvant chemotherapy: correlation between Ki-67 expression and pathological response. Asian Pac J Cancer Prev 17(2):807–813

Article  PubMed  Google Scholar 

van den Ende NS, Nguyen AH, Jager A, Kok M, Debets R, van Deurzen CHM (2023) Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review. Int J Mol Sci 24(3):2969

Article  PubMed  PubMed Central  Google Scholar 

Vörös A, Csörgő E, Kővári B, Lázár P, Kelemen G, Rusz O, Nyári T, Cserni G (2015) Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy. Pathol Oncol Res 21(1):147–155

Article  PubMed  Google Scholar 

Yamazaki N, Wada N, Yamauchi C, Yoneyama K (2015) High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy. Eur J Surg Oncol 41(5):617–624

Article  PubMed  Google Scholar 

Matsubara N, Mukai H, Fujii S, Wada N (2013) Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Breast Cancer Res Treat 137(1):203–212

Article  PubMed  Google Scholar 

Hafeez F, Neboori HJ, Harigopal M, Wu H, Haffty BG, Yang Q, Schiff D, Moran MS (2013) Is Ki-67 expression prognostic for local relapse in early-stage breast cancer patients treated with breast conservation therapy (BCT)? Int J Radiat Oncol Biol Phys 87(2):344–348

Article  PubMed  Google Scholar 

Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T et al (2011) Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in Breast Cancer working group. J Natl Cancer Inst 103(22):1656–1664

Article  PubMed  PubMed Central  Google Scholar 

Ludvigsson JF, Appelros P, Askling J, Byberg L, Carrero JJ, Ekström AM, Ekström M, Smedby KE, Hagström H, James S et al (2021) Adaptation of the Charlson Comorbidity index for register-based research in Sweden. Clin Epidemiol 13:21–41

Article  PubMed  PubMed Central  Google Scholar 

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67(2):93–99

Article  PubMed  Google Scholar 

Corben AD, Abi-Raad R, Popa I, Teo CH, Macklin EA, Koerner FC, Taghian AG, Brachtel EF (2013) Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application. Arch Pathol Lab Med 137(8):1074–1082

Article  PubMed  Google Scholar 

Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ et al (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer. Ann Oncol 28(8):1700–1712

Article  PubMed  PubMed Central  Google Scholar 

Janeva S, Krabbe E, Parris TZ, Nasic S, Sundquist M, Karlsson P, Audisio RA, Olofsson Bagge R, Kovács A (2023) Clinical evaluation of molecular surrogate subtypes in patients with ipsilateral multifocal primary breast cancer. Breast Cancer Res 25(1):36

Article  PubMed  PubMed Central  Google Scholar 

Yoshida K (2019) R package “tableone”: Create 'Table 1' to Describe Baseline Characteristics.